Emerging Screening Approaches in the Development of Nrf2-Keap1 Protein-Protein Interaction Inhibitors.

Area of Science:

• Biochemistry
• Pharmacology
• Drug Discovery

Background:

• The Keap1-Nrf2 protein-protein interaction (PPI) is vital for cellular defense against oxidative stress.
• Dysregulation of this pathway is implicated in diseases like cancer, neurodegenerative disorders, and diabetes.
• Targeting the Keap1-Nrf2 PPI with small molecules offers a therapeutic strategy for these conditions.

Purpose of the Study:

• To review and summarize virtual screening and other methods for identifying novel small molecule inhibitors of the Keap1-Nrf2 PPI.
• To discuss the advantages and limitations of various discovery strategies.
• To evaluate the potential of the Keap1-Nrf2 PPI as a drug target for disease therapy.

Main Methods:

• Comprehensive literature review of virtual screening techniques.
• Analysis of computational and experimental approaches for Keap1-Nrf2 inhibitor discovery.
• Discussion of drug development pathways and clinical translation challenges.

Main Results:

• Virtual screening and other methods have been employed to discover lead compounds targeting the Keap1-Nrf2 PPI.
• Several strategies show promise, but no inhibitors have reached clinical application yet.
• The Keap1-Nrf2 PPI remains a highly promising target for therapeutic intervention.

Conclusions:

• Novel strategies are needed to accelerate the identification and development of Keap1-Nrf2 inhibitors.
• Virtual screening offers a powerful approach to mine large databases for potential drug candidates.
• Further research into the Keap1-Nrf2 PPI could lead to new treatments for oxidative stress-related diseases.